Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Deferred Revenue: 2011-2021

Historic Current Deferred Revenue for Abeona Therapeutics (ABEO) over the last 10 years, with Dec 2021 value amounting to $296,000.

  • Abeona Therapeutics' Current Deferred Revenue changed negligibly% to $296,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $296,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $296,000 for FY2021, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q4 2021, Abeona Therapeutics' Current Deferred Revenue is $296,000, which was down 0.00% from $296,000 recorded in Q3 2021.
  • In the past 5 years, Abeona Therapeutics' Current Deferred Revenue ranged from a high of $2.6 million in Q4 2017 and a low of $296,000 during Q4 2018.
  • Its 3-year average for Current Deferred Revenue is $296,000, with a median of $296,000 in 2021.
  • As far as peak fluctuations go, Abeona Therapeutics' Current Deferred Revenue spiked by 331.89% in 2017, and later crashed by 88.62% in 2018.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Current Deferred Revenue stood at $2.6 million in 2017, then tumbled by 88.62% to $296,000 in 2018, then crashed by 45.59% to $296,000 in 2019, then remained steady at $296,000 in 2020, then remained steady at $296,000 in 2021.
  • Its last three reported values are $296,000 in Q4 2021, $296,000 for Q3 2021, and $296,000 during Q2 2021.